The drug works on OA, not just OA of the knee as the first trials narrowly targeted. This is seen in the way the drug is used by vets and some of the feedback from participants in the trials to date. Hopefully a trial of over 1000 people will also allow this to be established to a level of scientific confidence that means it can be marketed broadly.
Ann: Paradigm EOFY Update, page-33
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $83.95M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.3¢ | 24.0¢ | $29.73K | 123.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 115944 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 71879 | 11 |
View Market Depth
| Last trade - 11.55am 12/06/2024 (20 minute delay) ? |
|
|||||
|
Last
24.3¢ |
Change
0.000 ( 0.12 %) |
||||
| Open | High | Low | Volume | ||
| 24.3¢ | 24.3¢ | 24.0¢ | 7403 | ||
| Last updated 12.15pm 12/06/2024 ? | |||||
| PAR (ASX) Chart |